News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Almac Discovery Announce Commencement of Phase I Trials of Granisetron Nasal Spray



12/15/2009 10:20:29 AM

Bookmark and Share

CRAIGAVON, UNITED KINGDOM--(Marketwire - December 15, 2009) - Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).

CINV is experienced by around 80% of patients currently receiving chemotherapy. Acute CINV typically occurs within minutes or hours of drug administration and can last for up to 24 hours. 5-HT3 antagonists like Granisetron are often first choice therapies but have to be given orally or via injection. It is anticipated that this novel intranasal formulation of Granisetron will provide convenient and significant relief from these side effects of chemotherapeutic drugs.

The clinical trial, expected to complete in early 2010, will evaluate the safety, bioavailability and pharmacokinetics of single doses of intranasal Granisetron compared with oral and intravenous formulations.

Dr Stephen Barr, Managing Director and President of Almac Discovery, said: "The initiation of this Phase I study with intranasal Granisetron is a significant further milestone for Almac Discovery. It underlines our commitment to improving the lives of patients receiving chemotherapy."

Dr Alan Smith, Vice President, Research & Development of Archimedes Development Ltd, the development company of Archimedes Pharma, commented: "Archimedes was pleased to use our experience in rapidly delivering product into clinical trials to facilitate the early commencement of the Granisetron Nasal Spray programme. Patients suffering from severe CINV or intractable vomiting are often unable to tolerate oral medication and nasal delivery will offer such patients a real alternative."

Under the agreement, Archimedes Development Ltd is responsible for developing the formulation through to the end of Phase I and will cooperate with Almac Discovery on the clinical development of the product.

Granisetron Nasal Spray incorporates ChiSys® licensed from Archimedes Development Ltd. ChiSys® is a trade mark of Archimedes Development Ltd. and is registered as a CTM, as a US Registered Trademark and in certain other jurisdictions.


Contacts:
Stakeholder Communications:
Carl Whyte
+44 28 9033 9949
carl.whyte@stakeholdergroup.com

Almac Discovery:
Rob Grundy
+44 2838 395794

For Archimedes
Capital MS&L
(for media enquiries):
Mary Clark, Supriya Mathur
+44 20 7307 5330

Trout International LLC
(for investor enquiries):
Mike Booth
+44 20 7936 9326


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES